The 36-month beta value for IONS is at 0.37. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 as “hold,” and 1 as “sell.”
The public float for IONS is 145.72M, and currently, shorts hold a 7.37% of that float. The average trading volume for IONS on November 15, 2024 was 1.54M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IONS) stock’s latest price update
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has seen a decline in its stock price by -1.46 in relation to its previous close of 37.78. However, the company has experienced a -3.20% decline in its stock price over the last five trading sessions. zacks.com reported 2024-11-07 that IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.
IONS’s Market Performance
Ionis Pharmaceuticals Inc (IONS) has experienced a -3.20% fall in stock performance for the past week, with a -4.93% drop in the past month, and a -19.87% drop in the past quarter. The volatility ratio for the week is 2.86%, and the volatility levels for the past 30 days are at 2.89% for IONS. The simple moving average for the past 20 days is -4.02% for IONS’s stock, with a -13.98% simple moving average for the past 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with BMO Capital Markets repeating the rating for IONS by listing it as a “Market Perform.” The predicted price for IONS in the upcoming period, according to BMO Capital Markets is $60 based on the research report published on August 02, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IONS reach a price target of $62, previously predicting the price at $53. The rating they have provided for IONS stocks is “Outperform” according to the report published on July 24th, 2024.
Jefferies gave a rating of “Buy” to IONS, setting the target price at $75 in the report published on July 16th of the current year.
IONS Trading at -6.62% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.62% of loss for the given period.
Volatility was left at 2.89%, however, over the last 30 days, the volatility rate increased by 2.86%, as shares sank -3.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.68% lower at present.
During the last 5 trading sessions, IONS fell by -3.20%, which changed the moving average for the period of 200-days by -27.55% in comparison to the 20-day moving average, which settled at $38.79. In addition, Ionis Pharmaceuticals Inc saw -26.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Swayze Eric, who sale 1,194 shares at the price of $37.92 back on Nov 12 ’24. After this action, Swayze Eric now owns 33,713 shares of Ionis Pharmaceuticals Inc, valued at $45,278 using the latest closing price.
Monia Brett P, the Chief Executive Officer of Ionis Pharmaceuticals Inc, sale 6,630 shares at $38.05 during a trade that took place back on Nov 12 ’24, which means that Monia Brett P is holding 167,393 shares at $252,294 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.5 for the present operating margin
- 0.91 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.48. The total capital return value is set at -0.13. Equity return is now at value -73.33, with -11.92 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at 2.25. The interest coverage ratio of the stock is -4.45.
Currently, EBITDA for the company is -230.01 million with net debt to EBITDA at -4.4. When we switch over and look at the enterprise to sales, we see a ratio of 9.38. The receivables turnover for the company is 41.39for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.91.
Conclusion
In conclusion, Ionis Pharmaceuticals Inc (IONS) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
